Role of claudin-6 in high-grade endometrial carcinoma: Implications for risk stratification and personalized treatment strategies

This commentary discusses the groundbreaking study by Ebrahim <i>et al</i> on the role of claudin-6 (CLDN6) in high-grade endometrial carcinoma, addressing a significant gap in current knowledge. Their research reveals that overexpression of CLDN6 is linked to unfavorable pathological features. Moreover, multivariate analysis establishes CLDN6 as an independent predictor of disease-free survival, with a hazard ratio of 68.98. These results highlight the promise of CLDN6 in improving risk stratification and as a potential therapeutic target, especially with the development of CLDN6-directed antibody-drug conjugates. To advance CLDN6 towards clinical application, further validation in prospective patient cohorts and studies exploring its interactions with other molecular pathways are essential.